【摘要】：目的:了解冠心病住院患者用藥現(xiàn)狀,為相關(guān)決策提供參考。方法:通過(guò)醫(yī)保系統(tǒng)提取綿陽(yáng)地區(qū)8家醫(yī)療機(jī)構(gòu)2014年1月-2016年12月冠心病患者病歷資料,每家醫(yī)療機(jī)構(gòu)抽取200份,采用Excel 2007、Access 2007、SPSS 19.0軟件對(duì)患者性別、年齡、用藥金額、藥品品種、藥品聯(lián)用情況等進(jìn)行統(tǒng)計(jì)分析。結(jié)果:共納入1 600例患者,其中男性893例,女性707例,平均年齡(73.9±10.2)歲。藥品費(fèi)用占住院總費(fèi)用的35.2%,冠心病治療藥物費(fèi)用占藥品費(fèi)用的72.4%,輔助治療用藥中的中成藥及4種改善循環(huán)的中藥提取成分的化學(xué)藥物費(fèi)用占冠心病治療藥物費(fèi)用的37.8%。主要治療用藥中,調(diào)脂藥物使用率為80.8%,血管緊張素轉(zhuǎn)化酶抑制劑(ACEI)和血管緊張素受體拮抗藥(ARB)的使用率為46.9%�？寡“逅幬锫�(lián)用質(zhì)子泵抑制劑(PPIs)者占抗血小板藥物使用者的54.9%;14例患者使用了短效的硝苯地平片;42例患者聯(lián)用了氯吡格雷和奧美拉唑。結(jié)論:左卡尼汀等輔助用藥費(fèi)用占比較高;ACEI或ARB、調(diào)脂藥物在冠心病患者中使用比例較低,選用短效鈣通道阻滯藥、雙嘧達(dá)莫欠合理;PPIs使用指征控制不嚴(yán);中成藥濫用較為明顯。
[Abstract]:Objective: to understand the current situation of drug use in patients with coronary heart disease (CHD) and to provide reference for relevant decision-making. Methods: the medical records of 8 medical institutions in Mianyang from January 2014 to December 2016 were collected. The patients' sex, age, amount of money and variety of drugs were analyzed by Excel 2007 access 2007 SPSS 19.0 software. Combined use of drugs and other statistical analysis. Results: a total of 1,600 patients were included, including 893 males and 707 females, with an average age of (73.9 鹵10.2) years. The cost of medicine accounted for 35.2g of the total cost of hospitalization, the cost of coronary heart disease (CHD) accounted for 72.4% of the cost of medicine, the cost of Chinese patent medicine in adjuvant treatment and the cost of four kinds of chemical drugs which improved the circulation of traditional Chinese medicine components accounted for 37.8% of the cost of coronary heart disease treatment. The utilization rate of lipid-regulating drugs was 80.8, and that of angiotensin converting enzyme inhibitor (ACEI) and angiotensin receptor antagonist (ARB) was 46.9%. Anti-platelet drugs combined with proton pump inhibitor (PPIs) accounted for 54.9% of antiplatelet drug users in 14 patients who received short-acting nifedipine tablets in combination with clopidogrel and omeprazole. Conclusion: the cost of levacarnitine and other adjuvant drugs is low in patients with coronary heart disease. The use of short-acting calcium channel blocker and dipyridamole is not strictly controlled and the abuse of Chinese patent medicine is obvious.
【作者單位】： 西南醫(yī)科大學(xué)藥學(xué)院;綿陽(yáng)市中心醫(yī)院藥學(xué)部;川北醫(yī)學(xué)院藥學(xué)系;
【基金】：四川省基層衛(wèi)生事業(yè)發(fā)展研究中心重點(diǎn)項(xiàng)目(No.SWFZ16-Z-07)
【分類號(hào)】：R541.4

【相似文獻(xiàn)】

相關(guān)期刊論文 前4條

1 周長(zhǎng)文;沈顯群;賈駿;王懿釩;冷志宏;羅素新;;糖尿病合并冠心病老年患者氯吡格雷抵抗的危險(xiǎn)因素分析[J];檢驗(yàn)醫(yī)學(xué)與臨床;2014年10期

2 劉光全;付菊;;重慶市永川區(qū)老年冠心病合并糖尿病患者的高危因素分析及干預(yù)對(duì)策[J];檢驗(yàn)醫(yī)學(xué)與臨床;2014年10期

3 胡艷;肖踐明;;光學(xué)相干斷層成像技術(shù)在冠心病臨界病變中的應(yīng)用[J];臨床醫(yī)學(xué);2014年05期

4 溫成泉,劉敏;陣發(fā)性室上性心動(dòng)過(guò)速的特點(diǎn)及合理用藥[J];實(shí)用心電學(xué)雜志;2003年02期

相關(guān)博士學(xué)位論文 前2條

1 何晨;臨床因素和解剖因素聯(lián)合應(yīng)用對(duì)冠心病介入術(shù)后患者遠(yuǎn)期預(yù)后的預(yù)測(cè)價(jià)值[D];北京協(xié)和醫(yī)學(xué)院;2017年

2 張麗娜;遺傳變異與PCI術(shù)后冠心病患者臨床預(yù)后的關(guān)系及多種遺傳位點(diǎn)檢測(cè)方法比較[D];華中科技大學(xué);2015年

，

本文編號(hào)：2236540